🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Muscle Growth5 cited studies

Sermorelin

Synthetic GHRH(1-29) — stimulates pituitary GH release for anti-aging and recovery.

SummaryMechanismDosingSafetyStudies
Research use only — not for human consumption.

What it is

Sermorelin Acetate is a synthetic peptide that encourages the pituitary gland to increase growth hormone (GH) production, leading to gains in lean tissue, fat metabolism, energy, sleep, and tissue repair. Commonly used in hormone-replacement and anti-aging protocols for its natural support of vitality and overall wellness.

Mechanism of action

Sermorelin is the first 29 amino acids of human GHRH — the active fragment that binds GHRH receptors on the anterior pituitary, triggering pulsatile GH release. Because it works upstream of the pituitary, it preserves negative feedback and reduces overshoot.

Half-life: ~10–20 minutes.

Evidence summary

Decades of pediatric GH-deficiency data establish efficacy in stimulating natural GH secretion. Adult anti-aging use is largely off-label; published work supports HPA preservation and a favorable safety profile.

Pantheon dosing guide

Application
Subcutaneous injection.
BAC Water
2 mg: 2 ml 5 mg: 2.5 ml
Dose
2 mg: 10 units (100 mcg) to 20 units (200 mcg). 5 mg: 5 units (100 mcg) to 10 units (200 mcg).
Frequency & Cycle Length
2 mg: 5 days on / 2 days off. 4 weeks. 5 mg: 5 days on / 2 days off. 5 weeks.
Timing
First thing in the morning, 2 hours after eating, or before bedtime.
Key Benefits
Stimulates natural growth hormone release. Supports muscle growth and fat loss. Improves sleep and recovery. Enhances energy and vitality.

Additional research protocol context

The printed guide above is Pantheon's dosing reference. These broader research examples are provided as context and may use different schedules.

  • 200–300 mcg subcutaneous, once daily before bed
  • Often stacked with Ipamorelin for synergistic GH release
  • 12-week cycles, repeat after 4–8 weeks off

Side effects & safety

  • Injection-site redness or itching
  • Transient flushing or headache
  • Generally well-tolerated relative to direct GH

Cited studies

  1. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Journal of Clinical Endocrinology & Metabolism.
    Read source ↗
  2. (1993). Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatrica Supplement.
    Read source ↗
  3. (1993). Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatrica Supplement.
    Read source ↗
  4. (1988). Growth hormone releasing hormone or growth hormone treatment in growth hormone insufficiency?. Archives of Disease in Childhood.
    Read source ↗
  5. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs.
    Read source ↗
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.